Search

Introduction: Asthma is a common inflammatory disease of airway affecting both adults and children. In a large number of cases asthma remains poorly controlled. There is a need to find an additional therapeutic demeanour alleviating symptoms and lowering the risk complications in a long-term. Recently, increasing number of studies has been examining dietary supplements in regards to their anti-inflammatory, immunomodulatory, anti-remodelling properties and their use in asthmatic patients. Aim of the Study: The aim of the study was to collect and analyse current literature regarding influence of different dietary supplements on the course of asthma in both adults and children. Methods and Materials: Extensive research was conducted using PubMed and Google Scholar, with the primary focus on literature from the past 5 years. Firstly, potential dietary supplements affecting course of asthma were collected. The names of the substances were juxtaposed with term “Asthma” to gather data regarding their effect on occurrence and control of asthma and potential mechanisms responsible for it. Additionally, references from selected articles were included in the analysis. Results: Dietary supplements show promising results in decreasing asthma symptoms and lowering inflammation of airway. However, our study revealed that in current state of knowledge there is a deficit of studies performed on humans, especially large-scale, prospective studies that assess the efficacy of different doses of dietary supplements. Thus, further research of dietary supplements in asthma is needed, especially large-scale randomised controlled trials.

Introduction: Bladder cancer is one of the most common cancers in the world. There are two forms of bladder cancer: non-muscle invasive bladder cancer and muscle invasive bladder cancer. A common treatment method for non- muscle invasive bladder cancer is intravesical BCG (Mycobaterium bovis) therapy after radical tumor resection. It is estimated that half of patients will have an insufficient response to BCG treatment. Patients using this type of therapy also report side effects more and more often. Aim of the study: The aim of this article is to discuss the latest discoveries in the treatment of non-muscle invasive bladder cancer when BCG therapy is insufficient. Material and Methods: The paper was created based on the PubMed and Scholar database. The literature was reviewed using the key words: „bladder cancer”; „BCG”; „treatment”; „side effects”; „novel therapies”. Results: The research shows that novel therapies are effective and safe compared to the use of BCG. In such patients, atezolizumab, metformin or intravesical magnesium sulfate infusions may be used as an alternative. An innovative solution is the use of HIVEC - heated chemotherapy administered intravesically. There are also drugs that potentiate the action of BCG, making the therapy more effective. These include: sasanlimab and rapamycin. Due to the side effects experienced by patients, the use of intravesical BCG is often replaced with intravesical infusions of chemotherapy drugs. Conclusion: The research shows that novel therapies are effective compared to the use of BCG. Unfortunately, more research is needed to standardize the treatment of non-muscle invasive bladder cancer.